Abstract:Objective To observe the clinical effect of Valsartan combined with Amlodipine in the treatment of renal hypertension.Methods All of 86 patients with chronic kidney disease complicated with renal hypertension treated in our hospital from January 2014 to June 2017 were selected,the patients were divided into two groups by randomly number table method,and each group had 43 cases.The observation group was treated by Valsartan combined with Amlodipine,the control group was treated by only Valsartan.The two groups were treated 4 courses.The blood pressure,changes in renal function indicators,medication safety of the two groups were observed.Results the total effective rate of the observation group was higher than that of the control group,and there was a statistical significance (P<0.05).After treatment,the level of SBP and DBP in both groups were lower than those in the control group and the level of SBP and DBP in the observation group were lower than those in the control group(P<0.05).The level of SCr,BUN and 24 h urine protein in the two groups were lower than those before treatment and the glomerular filtration rate (GFR)level of the observation group was higher than that before treatment,and the differences were statistically significant(P<0.05).The level of SCr,BUN and 24 h urine protein in the observation group were lower than those of the control group,and the level of GFR was higher than that of the control group (P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).Conclusion The effect of Valsartan combined with Amlodipine in treatment of patients with renal hypertension is exact,it has significant effect in lowering blood pressure and protecting of renal function in patients,and the drugs were highly safety,It can be vigorously promoted in clinic.
倪丽. 缬沙坦联合氨氯地平治疗肾性高血压患者的临床效果分析[J]. 中国当代医药, 2018, 25(14): 21-24.
NI Li. Clinical effect analysis of Valsartan combined with Amlodipine in treatment of patients with renal hypertension. 中国当代医药, 2018, 25(14): 21-24.